Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + IE in Relapsed/Refractory Osteosarcoma
NCT04824352Phase 2Suspended
- Sponsor
- Peking University People's Hospital
- Start
- Apr 2021
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in osteosarcoma (OS), sponsored by Peking University People's Hospital. Started Apr 2021; status: suspended.
02
Drugs
Rivoceranib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT04824352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04824352.